As Silverback admits defeat, ARS troops forward to fund commercialization of epinephrine nasal spray
ARS Pharmaceuticals is backing onto Nasdaq through a reverse merger with Silverback Therapeutics to bag cash to commercialize an epinephrine nasal spray and win market share from the incumbent EpiPen.
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The What: MultiDyne Fiber Optic Solutions has designated IBC2018 as the European debut of ...
Silverback Therapeutics is on a roll. After banking more than $160 million in venture capital this year, the immuno-oncology biotech filed on Tuesday to raise up to $100 million in its Wall Street ...
After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-oncology biotech is picking up another $85 million to advance its lead antibody-drug conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback